Skip Ribbon Commands
Skip to main content
Skip to main navigation Skip to main content
Sign In

Martindale Pharma, Pierre Fabre, Janssen and Pharmasure have been named in advertisements(1) following breaches of the ABPI Code of Practice for the Pharmaceutical Industry. In addition Pierre Fabre was publicly reprimanded.

18/07/2018
Press Release
All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

Martindale Pharma, Pierre Fabre, Janssen and Pharmasure have been named in advertisements(1) following breaches of the ABPI Code of Practice for the Pharmaceutical Industry. All have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, Pierre Fabre was publicly reprimanded.

Martindale Pharma – Case AUTH/2961/6/17

For advertising Espranor oral lyophilisate (buprenorphine) (substitution therapy for opioid dependence) to the public and for making claims in material aimed at patients and health professionals which were, inter alia, prejudicial to patient safety, Martindale was ruled in breach of the following clauses of the Code:

Clause 2      - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 7.2   - Providing misleading information

Clause 7.3   - Making misleading comparisons

Clause 7.4   - Making unsubstantiated claims

Clause 7.9   - Making claims that did not reflect the available evidence regarding possible adverse reactions

Clause 9.1   - Failing to maintain high standards

Clause 26.1 - Advertising a prescription only medicine to the public

Clause 26.2 - Providing unbalanced information and encouraging members of the public to ask for a specific prescription only medicine


Pierre Fabre – Case AUTH/2962/7/17

For briefing representatives about Toviaz (fesoterodine) using an uncertified presentation and failing to provide complete information, Pierre Fabre was ruled in breach of the following clauses of the Code:

Clause 2      - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 9.1   - Failing to maintain high standards

Clause 14.1 - Failing to certify promotional material

Clause 15.9 - Producing representatives' briefing material that did not comply with the relevant requirements of the Code

The Code of Practice Appeal Board publicly reprimanded Pierre Fabre for providing inaccurate information to the Panel.


Janssen – Case AUTH/2978/9/17

For promoting a medicine prior to the grant of its authorization Janssen was ruled in breach of the following clauses of the Code:

Clause 2         - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.1      - Promotion prior to the grant of the marketing authorization

Clause 9.1      - Failing to maintain high standards

 

Pharmasure – Case AUTH/3008/1/18

For providing a group of health professionals with a hamper of chocolates, Pharmasure was ruled in breach of the following clauses of the Code:

Clause 2         - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 9.1      - Failing to maintain high standards

Clause 18.1    - Providing a gift in connection with the promotion of medicines

 

Pierre Fabre – Case AUTH/3012/1/18

For failing to certify representatives' briefing materials and one presentation aimed at health professionals which promoted an unlicensed medicine, including briefing materials related to Toviaz (fesoterodine) that were misleading, not capable of substantiation, and which advocated a course of action likely to lead to a breach of the Code, Pierre Fabre was ruled in breach of the following clauses of the Code:

Clause 2         - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.1      - Promoting an unlicensed medicine

Clause 7.2      - Providing misleading information

Clause 7.4      - Making an unsubstantiated claim

Clause 9.1      - Failing to maintain high standards

Clause 14.1    - Failing to certify material

Clause 15.9    - Producing briefing material likely to lead to a breach of the Code


Notes to Editors: 

(1) The advertisements will appear in the British Medical Journal on 21 July, the Nursing Standard on 28 July and the Pharmaceutical Journal on 1st August 2018.  

The case reports were published in the PMCPA May 2018 Code of Practice Review; the public reprimand appeared on the front cover. The case reports and Code of Practice Review are available at www.pmcpa.org.uk.

For more information contact Elly Button ebutton@pmcpa.org.uk  0207 747 8884/ 07956437982.